Q-omics provides the consensus-scored ZNF239 profile across patient tissues and cancer cell-line models. ZNF239 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF239 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ZNF239 RNA expression shows 19,720 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where ZNF239 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF239 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF239 survival associations across molecular data types. ZNF239 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF239 RNA expression–survival associations across cancer types. High ZNF239 expression shows unfavorable associations in KIRP, COAD, LIHC and ACC, but favorable associations in UCS and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF239 RNA expression.
This table summarizes ZNF239 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF239. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF239 shows lower tumor expression in KICH and higher tumor expression in COAD, LUAD, STAD, KIRP and BRCA. The COAD box plot shows higher ZNF239 RNA expression in tumor versus normal tissue (log2 FC = +1.612, t-test p < 0.001).
This table shows molecular features associated with ZNF239 in patient tissues and cancer cell lines. In patient samples, ZNF239 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF239 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
